Table 2.
Overview of clinical trials on noninvasive imaging of PD-1:PD-L1.
| Probe | Label | Phase | Tumor type | Patients | Location | End | NCT n° | EUDRACT |
|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | 89Zr | Phase II | NSCLC | N=10 | Amsterdam, NL | Dec '19 | NCT03065764 | 2015-004260-10 |
| Atezolizumab | 89Zr | Phase I | Breast, bladder, NSCLC | N=30 | Groningen, NL | Jul '17 | NCT02453984 | 2015-000996-29 |
| Pembrolizimab | 89Zr | Phase I/II | Melanoma, NSCLC | N=21 | Groningen, NL | Jul '17 | NCT02760225 | 2016-000941-30 |
| Anti-PD-L1 Adnectin | 18F | Substudy of Phase III |
Melanoma | unknown | Amsterdam, NL | Apr '22 | 2015-004920-67 monocenter substudy |
|
| Anti-PD-L1 Adnectin Nivolumab |
18F 89Zr |
Feasibility | NSCLC | N=10 | Amsterdam, NL | Aug '18 | 2015-004760-11 | |
| Durvalumab | 89Zr | Feasibility | NSCLC | N=10 | Amsterdam, NL | Jul '20 | 2015-005765-23 | |
| Anti-PD-L1 Nb | 99mTc | Phase I | NSCLC | N=50 | Shangai, CHN | Dec '18 | NCT02978196 |
Abbreviations: CHN: China; mAb: monoclonal antibody; Nb: nanobody; NL: the Netherlands; NSCLC: non-small cell lung cancer; Tc: technetium; Zr: zirconium